Emostasi e Trombosi, Società Italiana di. 2026. “PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM : I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux De Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut De Recerca Germans Trias I Pujol, Hospital Universitari Germans Trias I Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma De Barcelona, Barcelona; 7Universidad Catolica San Antonio De Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology Unit, Arles, France; 10Assistance Publique - Hôpitaux De Paris, AGEPS, France; 11Service De Médecine Vasculaire Et Therapeutique, CHU De Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département De Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service De Pharmacologie Clinique, CHU De Saint-Etienne, Saint-Etienne, France”. Bleeding, Thrombosis and Vascular Biology 5 (s1). https://doi.org/10.4081/btvb.2026.528.